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Material and Methods: Thirty-four patients were included in 
a period from 1994 until 2013. Patients’ charts were 
reviewed to obtain patients’, treatment and tumor 
characteristics. DVH parameters were analyzed after 
reconstruction of the original brachytherapy plan plus 
delineation of intermediate risk CTV (CTVIR) and organs at 
risk. The target volume at time of BT was the GTVres and 
was defined by the treating doctor based on clinical 
examination and CT scan. The CTVIR was defined by the 
tumor extension at time of diagnosis. Survival rates were 
calculated using the Kaplan-Meier method. Morbidity was 
scored by CTCAE v3.0. 
 
Results: Nine (26%) patients had FIGO stages I; 13 (38%) II; 5 
(15%) III and 7 (21%) IVA. Median age at diagnosis was 68 
years (33-91). Median follow-up was 37 months (3-224). 
Thirty-two patients received whole pelvic external beam 
radiotherapy (EBRT) to a median dose of 46 Gy (45-50.4 Gy), 
followed by BT in 31 patients; two patients received BT 
alone. The median D90 and D98 of the GTVres were 68 Gy 
and 67 Gy respectively, with a median V100 of 88%. The 
median D90 and D98 of the CTVIR were 65 Gy and 61 Gy 
respectively, with a median V100 of 62%. Complete remission 
at 3 months was achieved in all but one patient. Overall 
survival (OS) rates at 2- and 5-years were respectively 76% 
and 41%. Eight (24%) patients had any grade ≥3 toxicity. Local 
recurrences were seen in seven (21%) patients of whom three 
had an isolated local recurrence. Patients’ and treatment 
characteristics of this group are shown in Table 1. Although 
the coverage of the GTVres seemed adequate, in retrospect 
it was often disputable if the tumor at BT was fully covered 
due to poor visibility of the tumor on CT scan. 
 
 
 
 
Conclusion: The combination of EBRT and BT with or without 
concomitant chemotherapy provides reasonable outcomes in 
terms of tumor control and toxicity. However, there is still 
room for improvement. This study was too small to illustrate 
clear dose-effect relationships. In general, the prescribed 
dose on target at time of BT (GTVres) seemed low. In 
addition, coverage of the CTVIR was poor, which can however 
be explained by the fact that until recently our target at BT 
was exclusively based on GTVres. Finally, the use of MRI at 
time of BT seems necessary to better define the target. 
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Purpose or Objective: To evaluate the treatment results, 
and complication rates in patients with locally advanced 
cervical cancer after external beam radiotherapy (EBRT) and 
high-dose rate (HDR) brachytherapy with dose escalation. 
 
Material and Methods: All patients with locally advanced 
cervical cancer (FIGO: IB 7 patients, II 10 patients, III 7 
patients, IV 4 patients) treated with radical radiotherapy in 
our center from 2007 to October 2015 were reviewed. 
Twenty eight patients were treated with EBRT using 
intensity-modulated radiation therapy (IMRT) technique 
following by HDR brachytherapy +/- chemotherapy. 
Planification included CT (50%) or PET-CT (50%) for GTV 
delineation. The most common prescription was 50.4 Gy 
(1.8Gy per fraction) for pelvic lymph nodes +/- paraaortic 
lymph node with concomitant boost up to 60, 48 Gy (2,16Gy 
per fraction) for macroscopic nodal disease and parametrium 
affectation. HDR brachytherapy was applied using tandem (25 
Gy in 5 fractions) in most patients. Toxicity was assessed 
according to RTOG-EORTC criteria. All statistical analysis was 
performed using SPSS vs 22.0. 
 
Results: There was no grade 3 acute toxicity associated with 
EBRT. Only one case of grade 4 acute toxicity was observed 
after HDR gynecological brachytherapy. The median age was 
51 years (range 39 – 81). The median of follow up was 30 
months (range 4 – 85). The actuarial progression-free survival 
was 77% at 36 months. Median time to local progression has 
not been reached. The median overall survival was 30 (range 
4-85) month. 
 
Conclusion: Radical radiotherapy +/- chemotherapy is still a 
standard treatment in locally advanced uterine cervical 
cancer with good local control and global survival. Dose 
escalation is possible using PET-CT and IMRT which allow 
better conformation and better tolerance.  
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Purpose or Objective: To determine clinical efficacy and 
toxicity of weekly nimotuzumab plus cisplatin concurrent 
with intensity-modulated radiotherapy in Chinese women 
with locally advanced cervical cancer. 
 
Material and Methods: Between December 2013 and July 
2015, a total of 27 patients with primary carcinoma of the 
cervix, FIGO stage IB1 to IVa, squamous cell carcinomas 
confirmed by histology were enrolled into this study. 26 
patients received intensity modulated radiotherapy and 5 ~ 6 
fractions HDR brachytherapy, 1 patient received intensity 
modulated radiotherapy followed by surgery because she had 
rectum carcinoma at the same time. Chemotherapy scheme 
was 200 mg nimotuzumab and 40 mg/m2 cisplatin weekly for 
six cycles. 2 patients (ages: 78 ~ 79) received only 200 mg 
nimotuzumab weekly for six cycles. The patients were 
